Status:
COMPLETED
COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).
Lead Sponsor:
Nasus Pharma
Conditions:
COVID-19
Upper Respiratory Tract Infections
Eligibility:
All Genders
12-120 years
Phase:
NA
Brief Summary
TAFFIX is a nasal powder spray that immediately creates a protective acidic barrier on the nasal mucosa against infection by inhaled viruses. The protective barrier lasts 5 hours. TAFFIX is approved ...
Detailed Description
Study Design: This is a 2 arms, Randomized, double blind, placebo controlled clinical trial. Study population: Subjects who, were not diagnosed with COVID-19 previously to their best knowledge and ...
Eligibility Criteria
Inclusion
- Subjects 12 yr and older who had not previously been infected with COVID-19 to the best of their knowledge.
- Were not vaccinated yet against COVID-19 and will not be vaccinated during the study (if they decide to get the vaccine during the study they will be excluded a week later).
- Negative serology rapid test to COVID-19.
- Be informed of the nature of the study and the procedures and sign an informed consent form.
- Willing and able to adhere to Protocol requirements.
- If female of childbearing potential, agree to use an acceptable method of birth control or be surgically sterile, and have a negative pregnancy test.
Exclusion
- Known sensitivity to citric acid and/or sodium citrate and /or benzalkonium chloride and /or Hydroxypropylmethylcellulose (HPMC) or lactose (does not mean diagnosed lactose intolerance in food).
- Females who are pregnant or are lactating as reported by the subject.
Key Trial Info
Start Date :
May 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 2 2021
Estimated Enrollment :
693 Patients enrolled
Trial Details
Trial ID
NCT05252468
Start Date
May 19 2021
End Date
December 2 2021
Last Update
March 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Diagnostics and Consultation Center Convex Ltd
Sofia, Bulgaria